Soufflé Therapeutics Secures $135M in Series B Funding

Soufflé Therapeutics, a Boston, MA-based biotechnology provider of an RNA therapy platform, has raised $135 million in a Series B financing round led by Juvia Group.

The company will use the funding to advance its three lead programs into clinical studies and expand its research pipeline.

What is Soufflé Therapeutics?

Soufflé Therapeutics develops RNA therapies designed to deliver treatments to specific cells and tissues. Its proprietary REMEDY (Receptor Mediated Delivery) platform identifies receptors that can carry therapies into targeted cells and develops binders, such as antibodies, to enable delivery.

Read More:Intellivisa Raises $3M in Pre-Seed Funding for Travel AI

The technology is designed to support treatments for diseases affecting muscle, the heart and other tissues. By targeting specific cells, the company aims to develop therapies with improved potency, safety and durability.

Its lead programs focus on facioscapulohumeral muscular dystrophy (FSHD), heart failure with reduced ejection fraction (HFrEF), and muscle and metabolic disorders.

How Much Funding Has Soufflé Therapeutics Raised?

Soufflé Therapeutics has raised $135 million in its latest Series B funding round. Details of previous funding rounds and the company's total funding to date were not provided.

Who Invested in Soufflé Therapeutics’ Series B Round?

The $135 million Series B round was led by Juvia Group.

Participating investors include:

• TCG Crossover Management
• BB Biotech
• Fidelity Management & Research Company
• Balyasny Asset Management
• A leading sovereign wealth fund
• Amgen Ventures
• ARCH Venture Partners
• Bessemer Venture Partners
• Breyer Capital
• The Invus Group
• Janus Henderson
• Leaps by Bayer
• Polaris Partners
• Safar Partners
• TAS Partners
• Temasek
• Vida Ventures

Why the Funding Matters

Soufflé Therapeutics will use the funding to move its three lead programs toward clinical studies. The company also plans to advance its research pipeline across additional cell types and tissues.

The investment will support the development of RNA therapies targeting muscle diseases, heart failure and other conditions.

Who founded Soufflé Therapeutics?

Soufflé Therapeutics was founded in 2021 by Amir Nashat.

The company is headquartered in Boston, Massachusetts, and focuses on developing targeted RNA delivery technology and therapies.

“The confidence this exceptional group of investors has placed in Soufflé supports our belief that the REMEDY™ cell-specific product engine can make an impact in patients' lives,” said Amir Nashat, Chief Executive Officer, Soufflé Therapeutics.

"Cell-selective delivery could change what medicines can achieve for patients across countless diseases. We believe Soufflé has the platform, the pipeline and the people to make it happen,” said Stefan Vitorovic, Co-Founder and Managing Director, Juvia Group. “Patients have waited long enough for real precision from targeted therapies.

Market and Business Growth

Soufflé Therapeutics is advancing three lead programs.

Its most advanced program targets striated muscle to treat FSHD, a muscle disease for which the source says no approved disease-modifying therapies are available. Its second program targets the phospholamban (PLN) gene in heart muscle cells to address HFrEF. The third program focuses on an undisclosed target for muscle and metabolic disorders.

The company's REMEDY platform is also being developed to support delivery across additional cell types and tissues.

What Happens Next?

Soufflé Therapeutics plans to advance its three lead programs into clinical studies while expanding its RNA therapy pipeline.

The company will continue developing its REMEDY platform to support targeted delivery across a wider range of tissues and diseases.

Read More:Health Care Startup Brellium Secures $23M in Funding